The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Cohort Consortium Resource Request, 2013Alpha-synuclein and Other Biomarkers in Biological Samples of LRRK2 Parkinson’s Disease
Objective/Rationale:
Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s pathology have been investigated in Parkinson’s disease (PD), and abnormal CSF protein levels (tau and phosphorylated tau, beta... -
Dyskinesia Challenge, 2013NOP Receptor Agonists for Preventing Levodopa-induced Dyskinesia
Objective/Rationale:
Dyskinesia (involuntary fractured, jerky movements) is a debilitating side effect of long-term levodopa treatment for Parkinson’s motor symptoms. Previous studies have... -
Cognition Biomarkers, 2013Alpha-synuclein and Cognitive Decline in Parkinson’s Disease
Objective/Rationale:
Variability in the SNCA gene (which encodes alpha-synuclein, the protein that clumps in Parkinson’s disease) is a major risk factor for PD. Using next-generation... -
Research Grant, 2013Comprehensive Structural and Molecular Phenotyping of Parkinson’s Disease Models
Objective/Rationale:
Parkinson’s disease (PD) pre-clinical models carrying relevant human PD gene mutations can provide important insights into the molecular mechanisms implicated in PD... -
LRRK2 Cohort Consortium Resource Request, 2013Peripheral Blood-based Transcript Biomarkers for Prediction of Parkinson Disease in LRRK2 Mutation Carriers
Objective/Rationale:
Currently, there is no known marker that can be found in the human blood that can help to predict Parkinson's disease (PD). There is also no marker that can help... -
LRRK2 Pharmacodynamic Assays, 2013Fluorescence Fluctuation Spectroscopy Assays to Monitor the Activity of LRRK2
Objective/Rationale:
LRRK2 is a major protein target for therapeutic treatment of Parkinson’s disease (PD). The lack of assays (experiment set-ups) available for measuring the activity of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.